PARSIPPANY, N.J.--(BUSINESS WIRE)--May. 2, 2012--
Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that financial
results for the company's first quarter ended March 31, 2012, will be
released before the market opens on Wednesday, May 9, 2012. The Pacira
management team will host a conference call to discuss the company's
financial results and recent and upcoming developments on Wednesday, May
9, 2012, at 9 a.m. ET. The call can be accessed by dialing
1-866-788-0542 (domestic) or 1-857-350-1680 (international) five minutes
prior to the start of the call and providing the passcode 72710882.
A replay of the call will be available approximately two hours after the
completion of the call and can be accessed by dialing 1-888-286-8010
(domestic) or 1-617-801-6888 (international), and providing the passcode
15078124. The replay of the call will be available for two weeks from
the date of the live call.
The live, listen-only webcast of the conference call can be accessed by
visiting the investors section of the company's website at investor.pacira.com.
A replay of the webcast will be archived on the Pacira website for two
weeks following the call.
Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) is an emerging specialty
pharmaceutical company focused on the clinical and commercial
development of new products that meet the needs of acute care
practitioners and their patients. The company's current emphasis is the
development of non-opioid products for postsurgical pain control, and
its lead product, EXPAREL® (bupivacaine liposome injectable suspension),
was commercially launched in the United States in April 2012. EXPAREL
and two other commercially available products utilize the Pacira
proprietary product delivery technology DepoFoam®, a unique platform
that encapsulates drugs without altering their molecular structure and
then releases them over a desired period of time. Additional information
about Pacira is available at http://www.pacira.com.
Source: Pacira Pharmaceuticals, Inc.
Pacira Pharmaceuticals, Inc.
James S. Scibetta, 973-254-3570